Future studies will examine their potential effects on substance use disorder
When semaglutide reaches the brain, it signals that the body is full , leading to: Less hunger and fewer food cravings Reduced calorie intake , which leads to weight loss Longer-lasting satiety , meaning people feel full for longer after eating Since obesity and metabolic disorders can contribute to chronic inflammation , weight loss may also lead to a reduction in inflammation in the body
A phone call may be required
Some patients experience faster eGFR decline or acute kidney injury events during GLP-1 use, usually linked to inadequate fluid intake, concurrent illness, or unrecognized baseline kidney disease
Significant Weight Changes : Unintended weight loss or gain should be evaluated
[DOI] [PMC free article] [PubMed] [Google Scholar] 29.Nauck M.A., Meier J.J